Estrobolome
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
The estrobolome is a component of the human gut microbiome made up of microbial genes and taxa that produce enzymes, most notably β-glucuronidase (GUS), that metabolize estrogens and influence their enterohepatic circulation and systemic bioavailability The estrobolome directs how much estrogen is reabsorbed from the gut after hepatic conjugation and biliary excretion. By deconjugating estrogen glucuronides and other conjugates, estrobolome enzymes can change metabolites back into active estrogens, potentially having an effect on estrogen responsive physiology and disease risk. Research on the estrobolome covers enzymology (gut β-glucuronidase activity), taxonomic contributors, and associations with conditions like hormone sensitive cancers, dermal health, and menopausal changes, although causal links are still uncertain.
The estrobolome is a component of the human gut microbiome made up of microbial genes and taxa that produce enzymes, most notably β-glucuronidase (GUS), that metabolize estrogens and influence their enterohepatic circulation and systemic bioavailability The estrobolome directs how much estrogen is reabsorbed from the gut after hepatic conjugation and biliary excretion. By deconjugating estrogen glucuronides and other conjugates, estrobolome enzymes can change metabolites back into active estrogens, potentially having an effect on estrogen responsive physiology and disease risk. Research on the estrobolome covers enzymology (gut β-glucuronidase activity), taxonomic contributors, and associations with conditions like hormone sensitive cancers, dermal health, and menopausal changes, although causal links are still uncertain.
Clinical relevance and associations
Research on the estrobolome is largely targeted towards microbial estrogen metabolism and its influence on hormone responsive physiology and disease in humans. Since β-glucuronidase can change the balance between conjugated and unconjugated estrogens, differences in estrobolome conditions has been explored as a potential contributor to differences in systemic estrogen availability. Observational studies and reviews have shown associations between β-glucuronidase activity and estrogen receptor-positive breast cancer. Higher fecal β-glucuronidase activity has been suggested as a factor that could increase circulating estrogen levels (although evidence is correlational and does not favor causation). Changes in the estrobolome have also been related to menopause. Changes in estrogen production during the menopausal transition appear to align with changes in the gut microbiome, including differences in the amount of bacterial species that code for β-glucuronidase. Some studies suggest menopause associated microbiome changes could influence estrogen metabolite profiles. Some research has suggested that the estrobolome may have an effect bone density, cardiovascular health, or dermal health. However, most findings are associative, and many expose several confounding factors - diet, body mass, antibiotic exposure, and alcohol use - all of which make it difficult to isolate the effect of microbial estrogen metabolism. Direct causation has not been observed in humans, and much of the current landscape of research supports caution in interpreting associations.
See also
β-Glucuronidase Estrogen Human microbiome
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338829882 under CC BY-SA 4.0; modifications have been made.